论文部分内容阅读
吡柔比星(pirarubicin)又称吡喃阿霉素(THPADM),是阿霉素的衍生物,在阿霉素结构的4′-O-位上接上四氢吡喃基,系最新一代蒽环类抗肿瘤药物。已经临床证实该药抗瘤谱广,疗效高,毒性低。我科应用吡柔比星治疗19例恶性血液系疾患,现将治疗方案和疗效、毒副作用报告如下。 临床资料与方法 一、临床资料:19例恶性血液系疾患中,恶性淋巴瘤17例,恶性组织细胞增生症1例,多发性骨髓瘤1例。恶性淋巴瘤包括非霍奇金淋巴瘤12例,霍奇金病5例,其中男性12例,年龄26～65岁,中位年龄50岁;女性5例,年龄28～41岁,中位年龄30岁。所有病例均经活检和/或骨髓检查证实诊断,恶性淋巴瘤并经B超和CT检查进行分期辅助,确定病变波及范围。
Pirarubicin, also known as pirarubicin (THPADM), is a derivative of doxorubicin, and is connected to tetrahydropyranyl at the 4′-O-position of the doxorubicin structure, the latest generation. Anthracycline antitumor drugs. It has been clinically proven that the drug has a broad anti-tumor spectrum, high efficacy, and low toxicity. Our department applied pirarubicin to treat 19 cases of malignant blood disorders. Now we report the treatment plan, efficacy and toxic side effects as follows. Clinical data and methods First, clinical data: 19 cases of malignant blood disorders, malignant lymphoma in 17 cases, malignant histiocytosis in 1 case, multiple myeloma in 1 case. Malignant lymphomas include 12 cases of non-Hodgkin’s lymphoma and 5 cases of Hodgkin’s disease, including 12 males, aged 26 to 65 years, median age at 50 years; female 5 cases, aged 28 to 41 years, median age 30 years old. All cases were diagnosed by biopsy and/or bone marrow examination. Malignant lymphomas were staged and assisted by B-ultrasonography and CT to determine the range of lesions.